GlassScriptPhysician profile
Marvin W Sexton
NPI 1659365138
$18,499.91
in general payments reported to CMS, 2019-2025
43 companies · $5,982 in 2025
The $5,982 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,893 · 2020: $1,767 · 2021: $2,109 · 2022: $2,097 · 2023: $1,943 · 2024: $2,708 · 2025: $5,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,710 · Education: $2,596 · Travel and Lodging: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,709.52 |
| Education | $2,596.37 |
| Travel and Lodging | $1,328.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,353.60 | 2022-2025 | |
| Glaxosmithkline, LLC. | $3,012.98 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,886.62 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,829.92 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Insmed, INC. | $732.54 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $634.13 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $594.66 | 2019-2025 | |
| Philips North America LLC | $535.99 | 2019-2024 | (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $479.03 | 2021-2025 | Glassia, Cuvitru, Hyqvia |
| United Therapeutics Corporation | $476.87 | 2019-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $451.96 | 2019-2025 | Dupixent |
| Amgen INC. | $442.66 | 2022-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $343.29 | 2021-2025 | |
| Mylan Specialty L.P. | $334.60 | 2019-2024 | Yupelri |
| Gilead Sciences, INC. | $314.53 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $269.66 | 2019-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $235.82 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $216.66 | 2019-2021 | |
| Axsome Therapeutics, INC. | $150.74 | 2023-2024 | Sunosi |
| Genentech USA, INC. | $134.85 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $98.68 | 2020-2024 | |
| Harmony Biosciences LLC | $96.28 | 2020-2025 | |
| Verona Pharma, INC. | $94.50 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $86.84 | 2019-2024 | Keytruda, Belsomra |
| Body Vision Medical INC. | $68.32 | 2024 | Lungvision |
| Vifor Pharma, INC. | $66.41 | 2024-2025 | Zemaira |
| Fisher & Paykel Healthcare INC | $64.87 | 2021-2022 | |
| Viatris Specialty LLC | $63.68 | 2025 | Yupelri |
| Circassia INC. | $52.41 | 2019 | |
| Eisai INC. | $46.76 | 2020-2021 | |
| Shire North American Group INC | $46.45 | 2019 | |
| Melinta Therapeutics, LLC | $43.22 | 2020 | |
| Allergan, INC. | $36.59 | 2020 | |
| 3b Medical, INC. | $34.56 | 2023-2025 | Luna |
| Tactile Systems Technology INC | $34.10 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Veran Medical Technologies, INC. | $28.39 | 2020 | |
| Ethicon INC. | $24.79 | 2022 | |
| Abbvie INC. | $18.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.20 | 2022 | |
| Inogen, INC. | $16.29 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Covidien LP | $15.06 | 2019 | |
| Baxter Healthcare | $14.02 | 2024 | Hillrom - Vest System Model 105 Home Care |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.